OSLO—Norway will delay its decision on whether to resume the use of AstraZeneca’s COVID-19 vaccine by up to three weeks, the Norwegian Institute of Public Health (FHI) said on Friday. Authorities on March 11 suspended the rollout of the vaccine after a small number of younger inoculated people were hospitalized for a combination of blood clots, bleeding, and a low count of platelets, some of whom later died. “We have decided to continue the pause and make a new decision by April 15,” FHI chief Camilla Stoltenberg told broadcaster NRK. “We have started several processes to map out whether there is causality and to have a better basis to establish the real risk and a cost-benefit analysis for different age groups. To get more knowledge, it is necessary to have more time.” Norway is one of over a dozen European countries to have suspended the rollout of the vaccine over …